Welcome to our dedicated page for Cocrystal Pharma SEC filings (Ticker: COCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding a virology textbook. Cocrystal Pharma’s 10-K alone details experimental influenza antivirals, partnership milestones, and cash runway assumptions that shape the company’s future. Finding the section that matters before the market reacts is the real challenge.
Stock Titan turns that challenge into a two-minute task. Our AI-powered summaries translate dense language into clear insights, flagging Cocrystal Pharma quarterly earnings report 10-Q filing highlights, cash-burn trends, and pipeline updates. Need to monitor Cocrystal Pharma Form 4 insider transactions real-time? We push alerts the moment an executive buys or sells. Curious about an unexpected collaboration? Our engine links the announcement to the exact Cocrystal Pharma 8-K material events explained section so you can gauge impact fast.
The platform covers every disclosure type—10-K annual report, 10-Q, 8-K, S-1, and the Cocrystal Pharma proxy statement executive compensation—with real-time EDGAR feeds. Investors routinely use it to:
- Track R&D spend and milestone payments without wading through footnotes
- Compare sequential trial expenditures across business segments
- Spot Cocrystal Pharma insider trading Form 4 transactions before broader news outlets
Whether you’re understanding Cocrystal Pharma SEC documents with AI for the first time or seeking a deeper Cocrystal Pharma earnings report filing analysis, our expert commentary and machine learning models surface what matters—pipeline progress, dilution risk, and revenue potential—so you make informed decisions quickly. It’s Cocrystal Pharma annual report 10-K simplified, every quarter, every filing.
Bank of Montreal (BMO) is offering US$425,000 of Senior Medium-Term Notes, Series K – “Digital Return Buffer Notes” – maturing 3 August 2026. The notes are linked to the worst performer of three U.S. equity benchmarks: the S&P 500, NASDAQ-100 and Russell 2000 (each a “Reference Asset”).
Key economic terms:
- Digital Return: 10.40% payable at maturity if the closing level of the Least Performing Reference Asset on 29 July 2026 (the Valuation Date) is ≥ 85% of its 27 June 2025 Initial Level (“Digital Barrier”).
- Buffer: first 15% downside is absorbed. If the Least Performing Reference Asset drops >15%, principal is reduced point-for-point beyond the buffer, exposing investors to a maximum loss of 85%.
- No periodic coupons; single payment at maturity.
- Issue price: 100%; agent’s commission 0.375%; estimated initial value: $981.99 per $1,000, reflecting embedded fees and hedging costs.
- Credit exposure: unsecured, unsubordinated obligations of BMO; CUSIP 06376EMN9; not FDIC or CDIC insured; not exchange-listed.
Illustrative payouts: any Final Level ≥ 85% triggers a fixed $1,104 per $1,000 note (10.40% gain). A Final Level of 80% returns $950 (-5%); 60% returns $750 (-25%); 0% returns $150 (-85%). Upside is capped at 10.40% irrespective of index performance.
Risk considerations include potential loss of up to 85% of principal, limited upside versus direct index exposure, secondary-market illiquidity (no listing; dealer market making discretionary), BMO credit risk, tax uncertainty (treated as prepaid derivative contracts), and a price-to-public that exceeds the bank’s modeled value.
The product may appeal to investors with a moderately bullish to sideways view on large-, mega- and small-cap U.S. equities over the next ~13 months who are willing to trade upside beyond 10.40% for a 15% buffer and accept issuer credit and liquidity risk.
FAQ
What is the current stock price of Cocrystal Pharma (COCP)?
What is the market cap of Cocrystal Pharma (COCP)?
What does Cocrystal Pharma Inc. focus on?
What technologies does Cocrystal Pharma use?
Who are Cocrystal Pharma's strategic partners?
What are the key challenges for Cocrystal Pharma?
How does Cocrystal Pharma differentiate itself from competitors?
What diseases does Cocrystal Pharma target?
What is the significance of nucleoside chemistry in Cocrystal's work?
What stage are Cocrystal Pharma's drug candidates in?
